Arcus Biosciences Reports Promising Trial Results

Arcus Biosciences ( (RCUS) ) has provided an announcement.

Arcus Biosciences recently shared promising interim results from its Phase 1/1b trial of casdatifan for treating heavily pre-treated metastatic clear cell renal cell carcinoma patients. The 100mg dose showed a confirmed objective response rate of 25% and a disease control rate of 81%, without unexpected safety concerns. Most adverse events were manageable, highlighting casdatifan’s potential as a safe and effective treatment option.

For a thorough assessment of RCUS stock, go to TipRanks’ Stock Analysis page.